XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
  IBS
   Ulcerative Colitis
  Liver
  GERD
  Constipation
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

IBS Channel
subscribe to IBS newsletter

Latest Research : Gastroenterology : IBS

   DISCUSS   |   EMAIL   |   PRINT
Budesonide Prolongs Remission of Crohn's Disease
Sep 14, 2005, 01:59, Reviewed by: Dr.

“Long-term treatment with budesonide is well-tolerated and the frequency and types of adverse events are similar to placebo. Safety of a long-term medication is obviously important, but how well a patient tolerates their medication is also important and can affect patient adherence to therapy.”

 
In a study published in The American Journal of Gastroenterology, researchers found that budesonide capsules are an effective treatment to prolong and maintain the period of remission of Crohn’s Disease. Previous studies have demonstrated that budesonide is effective for inducing remission of Crohn’s disease.

Four double-blind, placebo-controlled trials were conducted with identical protocols in which patients with Crohn’s Disease, and medically induced remission, received a treatment of oral budesonide for 12 months. Results showed that budesonide taken at 6 mg/day is effective for prolonging time to relapse and for significantly reducing rates of relapse.

“Long-term treatment with budesonide is well-tolerated and the frequency and types of adverse events are similar to placebo,” states lead researcher,William J. Sandborn, MD. “Safety of a long-term medication is obviously important, but how well a patient tolerates their medication is also important and can affect patient adherence to therapy.”

Crohn’s disease is a long-term disease that results from inflammation of the digestive tract. It is a debilitating sickness, even for patients who are classified as having mild to moderate disease. Currently, there are no treatment options available that prevents recurrence of symptoms.

“As stated, this disease is recurring in nature, so extending the time a patient can be symptom-free or with diminished symptoms is an important feature of treatment. Budesonide capsules are a treatment option for Crohn’s disease that has been shown in studies not only to be very effective in relieving symptoms, but also in extending the time before patients experience a recurrence.”
 

- This study is published in The American Journal of Gastroenterology.
 

www.blackwellpublishing.com

 
Subscribe to IBS Newsletter
E-mail Address:

 

Dr. William J. Sandborn is a board certified gastroenterologist with specific expertise in inflammatory bowel disease. He has published extensively in this field, both nationally and internationally.

About The American Journal of Gastroenterology
The American Journal of Gastroenterology, the official publication of the American College of Gastroenterology, is THE clinical journal for all practicing gastroenterologists, hepatologists and GI endoscopists. With an impact factor of 4.716, it is the authoritative clinical source in the field of gastroenterology. With a broad-based, rigorous, interdisciplinary approach, the journal presents the latest important information in the field of gastroenterology including original manuscripts, meta-analyses and reviews, health economic papers, debates and consensus statements of clinical relevance in gastroenterology. The reports will highlight new observations and original research, results with innovative treatments and all other topics relevant to clinical gastroenterology. Case reports highlighting disease mechanisms or particularly important clinical observations and letters on articles published in the Journal are included.


Related IBS News

Why smokers rarely suffer from ulcerative colitis
Exercise, eating right could ease IBS, diarrhea and constipation
Budesonide Prolongs Remission of Crohn's Disease
Genome wide approach to pinpoint gene activations in IBD
Certolizumab Shows Significant Benefit in Moderate to Severe Crohn’s Disease
Probiotic bacteria mixture VSL#3 ease ulcerative colitis pain
Pediatric Researchers Collaborate to Build Largest Inflammatory Bowel Disease Registry
Irritable bowel syndrome, frequent indigestion common in people with insomnia


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us